Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Candiolo – page 32

987 clinical trials in Candiolo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Candiolo at a glance
987
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

987 trials in Candiolo

Open in trial search

Chronic lymphocytic leukaemia

Recruiting

Study of venetoclax, obinutuzumab and zanubrutinib combination therapy in young patients with high-risk Chronic Lymphocytic Leukemia and residual disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Allopurinol
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Myocarditis

Recruiting

Study on the Safety and Effectiveness of Methylprednisolone Sodium Succinate and Sodium Chloride for Patients with Severe Cardiac Inflammation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:ASST Grande Ospedale Metropolitano Niguarda

Glomerulonephritis membranoproliferative

Recruiting

Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Dementia Alzheimer's type

Recruiting

Study on the Effects of Rotigotine and Rivastigmine in Patients with Mild to Moderate Alzheimer's Disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rotigotine
  • Sponsor:Fondazione Santa Lucia

Small cell lung cancer+1

Recruiting

Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Boehringer Ingelheim International GmbH

Acute lymphocytic leukaemia+4

Recruiting

Study on Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for Children with Relapsed or Refractory Blood Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Trametinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Follicular lymphoma

Recruiting

Study on Radiotherapy Alone or with Obinutuzumab for Patients with Early Stage Follicular Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Fondazione Italiana Linfomi Ets

Glycogen storage disease type II

Recruiting

Study on the Safety and Effects of Cipaglucosidase Alfa and Miglustat for Children with Infantile-onset Pompe Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Miglustat
  • Sponsor:Amicus Therapeutics Inc.

Pericarditis

Recruiting

Study Comparing Anakinra and Prednisone for Children with Colchicine-Resistant Recurrent Pericarditis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Anakinra
  • Sponsor:IRCCS Istituto Giannina Gaslini

Plasma cell myeloma

Recruiting

Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Mantle cell lymphoma

Recruiting

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Chronic lymphocytic leukaemia recurrent

Recruiting

Study on Venetoclax and Obinutuzumab for Adults with Recurring Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Candiolo

What the registry says about research in the country

01 Hematologic Malignancies

Advanced research focusing on blood cancers including innovative treatments for myelodysplastic syndromes, follicular lymphoma, and chronic myelomonocytic leukemia. Studies evaluate novel drug combinations and maintenance therapies to improve patient outcomes.

  • Multiple Myeloma Treatment Optimization
  • Lymphoma Therapy Innovations
  • Leukemia Treatment Strategies

Trials investigate targeted therapies and immunotherapy approaches for better disease management.

02 Solid Tumors

Comprehensive research on lung cancer, breast cancer, and colorectal cancer. Studies explore combination therapies involving immunotherapy, targeted agents, and conventional treatments to enhance treatment efficacy.

  • Advanced NSCLC Treatments
  • Metastatic Disease Management
  • Novel Drug Combinations

Focus on personalized medicine approaches and biomarker-driven treatment selection.

03 Rare Cancers

Dedicated research into sarcomas, head and neck cancers, and other rare malignancies. Studies evaluate novel therapeutic approaches including immunotherapy combinations and targeted treatments.

  • Osteosarcoma Treatments
  • Soft Tissue Sarcoma Therapy
  • Innovative Treatment Protocols

Emphasis on developing effective treatments for cancers with limited therapeutic options.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.